Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins  |  March 9, 2020

She was diagnosed with rheumatoid factor-positive, polyarticular JIA.

“These [JIA] patients can be rheumatoid factor positive or negative—although it’s rare to see a positive rheumatoid factor in JIA,” Ms. Kremer said. “It accounts for less than 5% of patients. When positive, it’s considered the equivalent to the adult form of rheumatoid arthritis.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In this form of JIA, joints are often involved symmetrically, with both large and small joints affected. Fewer than 50% of these patients go into remission without medications.

Along with the medications considered for the previous case, biologics are an option. If a patient doesn’t respond to one anti-tumor necrosis factor (TNF) drug, such as adalimumab, etanercept or infliximab, they may respond to another anti-TNF, she said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Other treatment options include the CTLA-4 inhibitor, abatacept, and the IL-6-inhibitor, tocilizumab. All of these treatments require monitoring with complete blood count (CBC) and liver function tests. With tocilizumab, periodic lipid panels are also needed, Dr. Lynton noted.

Clinicians treated the patient in the second case with 0.5 mg/kg subcutaneous methotrexate weekly, as well as oral folic acid daily and 8 mg of ondansetron every eight hours for nausea, or as needed. At the same time, 0.8 mg/kg etanercept was given every week. The patient was on a nonsteroidal anti-inflammatory drug (NSAID), with the plan of stopping it upon remission. Baseline testing and subsequent monitoring were needed for tuberculosis, hepatitis B, hepatitis C, serum creatinine and CBC with differential and liver function tests.

Biologics
Despite the increased care necessary to monitor such patients, the use of biologics has been a huge step forward in the field. Dr. Lynton showed a picture of a mother who didn’t have access to biologics at the start of her disease and had hands with permanent, disfiguring damage. She was seated next to her son with JIA, who had been treated early with biologics and had hands that appeared normal.

“Biologics have revolutionized the outcomes in polyarticular JIA,” said Dr. Lynton.


Thomas R. Collins is a freelance writer living in South Florida.

Page: 1 2 3 | Single Page
Share: 

Filed under:Conditions Tagged with:2019 ACR/ARP Annual Meetingpediatric arthritisPediatric RheumatologyPediatrics

Related Articles

    Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

    March 12, 2020

    ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    What Adult Rheumatologists Need to Know about Juvenile Arthritis

    May 1, 2013

    How to recognize distinctions between pediatric and adult arthritis

    Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis

    July 1, 2014

    Physicians at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco report on studies about JAK inhibitors as targeted immunomodulators and disease-modifying therapies in RA

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences